The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

Subjects: Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

Subjects: Get full text

Electrostatic properties of human germlines and biodistribution of small biologics by Leticia Maria De Souza Cordeiro, Kelley Christine Atkinson, Argin Aivazian, Patrick Frank Joyce, Fang Jia, Alessandro Mascioni

Subjects: Get full text

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer by Hanghang Ma, Jianbin Li

Subjects: “…Antibody-drug conjugate…”
Get full text

Six events that shaped antibody approvals in oncology by Suman Paul, Suman Paul, Shibin Zhou, Shibin Zhou

Subjects: Get full text

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

Subjects: Get full text

Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli by Jacquelyn Blake-Hedges, Dan Groff, Wilson Foo, Jeffrey Hanson, Elenor Castillo, Miao Wen, Diana Cheung, Mary Rose Masikat, Jian Lu, Young Park, Nina Abi Carlos, Hans Usman, Kevin Fong, Abigail Yu, Sihong Zhou, Joyce Kwong, Cuong Tran, Xiaofan Li, Dawei Yuan, Trevor Hallam, Gang Yin

Subjects: “…Antibody–drug conjugate…”
Get full text

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer by Xiaojie Chu, Seungmin Shin, Du-San Baek, Liyong Zhang, Alex Conard, Megan Shi, Ye-Jin Kim, Cynthia Adams, Maggie Hines, Xianglei Liu, Chuan Chen, Zehua Sun, Dontcho V. Jelev, John W. Mellors, Dimiter S. Dimitrov, Wei Li

Subjects: “…Antibody drug conjugate…”
Get full text

Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis by Qi Xu, Xiaoyu Feng, Siyuan Qin, Yu Hong, Rui Cui, Jia Liang, Zhuya Xiao, Yuan Li

Subjects: Get full text

Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models by Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, Song S

Subjects: Get full text

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis by Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, Francisco Cezar Aquino de Moraes, Guilherme Rossato de Almeida, Lis Victória Ravani, Maysa Vilbert, Ricardo Lima Barros Costa

Subjects: Get full text

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development by Whi-An Kwon, Ho Kyung Seo, Geehyun Song, Min-Kyung Lee, Weon Seo Park

Subjects: “…antibody–drug conjugates…”
Get full text

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects by Yufei Wang, Guangliang Li, Hanying Wang, Quan Qi, Xian Wang, Haiqi Lu

Subjects: Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: Get full text

Biparatopic antibodies: therapeutic applications and prospects by David L. Niquille, Kyle M. Fitzgerald, Nimish Gera

Subjects: Get full text

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Subjects: Get full text